(Q35027813)

5 August 2017

1 reference

title

Dendritic cell gene therapy (English)

1 reference

5 August 2017

0 references

1 reference

Mark Onaitis

1 reference

5 August 2017

Matthew F Kalady

series ordinal

1 reference

5 August 2017

Scott Pruitt

series ordinal

1 reference

5 August 2017

Douglas S Tyler

series ordinal

1 reference

5 August 2017

publication date

1 July 2002

1 reference

Surgical oncology clinics of North America

5 August 2017

published in

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

645-660

1 reference

Small amounts of superantigen, when presented on dendritic cells, are sufficient to initiate T cell responses

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Dendritic cells resurrect antigens from dead cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Immunobiology of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Mobilizing dendritic cells for tolerance, priming, and chronic inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Human Dendritic Cells Transfected with RNA Encoding Prostate-Specific Antigen Stimulate Prostate-Specific CTL Responses In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Dendritic cells injected via different routes induce immunity in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Enhanced dendritic cell antigen presentation in RNA-based immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Production of IL-12 by human monocyte-derived dendritic cells is optimal when the stimulus is given at the onset of maturation, and is further enhanced by IL-4

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1055-3207%2802%2900027-3

7 January 2021

10.1016/S1055-3207(02)00027-3

Identifiers

DOI

1 reference

5 August 2017

1 reference